• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2022 Feb 21;22(1):174.
doi: 10.1186/s12879-022-07161-4.
Severe Acute Respiratory Syndrome Coronavirus-2 seroprevalence in South-Central Uganda, during 2019-2021


Charles Ssuuna[SUP] 1 [/SUP], Ronald Moses Galiwango[SUP] 2 [/SUP], Edward Nelson Kankaka[SUP] 2 [/SUP], Joseph Kagaayi[SUP] 2 3 [/SUP], Anthony Ndyanabo[SUP] 2 [/SUP], Godfrey Kigozi[SUP] 2 [/SUP], Gertrude Nakigozi[SUP] 2 [/SUP], Tom Lutalo[SUP] 2 4 [/SUP], Robert Ssekubugu[SUP] 2 [/SUP], John Bosco Wasswa[SUP] 2 [/SUP], Anthony Mayinja[SUP] 2 [/SUP], Martina Cathy Nakibuuka[SUP] 2 [/SUP], Samiri Jamiru[SUP] 2 [/SUP], John Baptist Oketch[SUP] 2 [/SUP], Edward Muwanga[SUP] 5 [/SUP], Larry William Chang[SUP] 2 6 7 8 [/SUP], Mary Kate Grabowski[SUP] 7 [/SUP], Maria Wawer[SUP] 2 7 [/SUP], Ronald Gray[SUP] 2 7 [/SUP], Mark Anderson[SUP] 9 [/SUP], Michael Stec[SUP] 9 [/SUP], Gavin Cloherty[SUP] 9 [/SUP], Oliver Laeyendecker[SUP] 8 [/SUP], Steven James Reynolds[SUP] 7 8 10 [/SUP], Thomas C Quinn[SUP] 8 10 [/SUP], David Serwadda[SUP] 2 3 [/SUP]



Affiliations

Abstract

Background: Globally, key subpopulations such as healthcare workers (HCW) may have a higher risk of contracting SARS-CoV-2. In Uganda, limited access to Personal Protective Equipment and lack of clarity on the extent/pattern of community spread may exacerbate this situation. The country established infection prevention/control measures such as lockdowns and proper hand hygiene. However, due to resource limitations and fatigue, compliance is low, posing continued onward transmission risk. This study aimed to describe extent of SARS-CoV-2 seroprevalence in selected populations within the Rakai region of Uganda.
Methods: From 30th November 2020 to 8th January 2021, we collected venous blood from 753 HCW at twenty-six health facilities in South-Central Uganda and from 227 population-cohort participants who reported specific COVID-19 like symptoms (fever, cough, loss of taste and appetite) in a prior phone-based survey conducted (between May and August 2020) during the first national lockdown. 636 plasma specimens collected from individuals considered high risk for SARS-CoV-2 infection, prior to the first confirmed COVID-19 case in Uganda were also retrieved. Specimens were tested for antibodies to SARS-CoV-2 using the CoronaChek™ rapid COVID-19 IgM/IgG lateral flow test assay. IgM only positive samples were confirmed using a chemiluminescent microparticle immunoassay (CMIA) (Architect AdviseDx SARS-CoV-2 IgM) which targets the spike protein. SARS-CoV-2 exposure was defined as either confirmed IgM, both IgM and IgG or sole IgG positivity. Overall seroprevalence in each participant group was estimated, adjusting for test performance.
Results: The seroprevalence of antibodies to SARS-CoV-2 in HCW was 26.7% [95%CI: 23.5, 29.8] with no difference by sex, age, or cadre. We observed no association between PPE use and seropositivity among exposed healthcare workers. Of the phone-based survey participants, 15.6% [95%CI: 10.9, 20.3] had antibodies to SARS-CoV-2, with no difference by HIV status, sex, age, or occupation. Among 636 plasma specimens collected prior to the first confirmed COVID-19 case, 2.3% [95%CI: 1.2, 3.5] were reactive.
Conclusions: Findings suggest high seroprevalence of antibodies to SARS-CoV-2 among HCW and substantial exposure in persons presenting with specific COVID-19 like symptoms in the general population of South-Central Uganda. Based on current limitations in serological test confirmation, it remains unclear whether seroprevalence among plasma specimens collected prior to confirmation of the first COVID-19 case implies prior SARS-CoV-2 exposure in Uganda.

Keywords: COVID-19; Healthcare workers; SARS-CoV-2 seroprevalence; South-Central Uganda.
 
Back
Top Bottom